Select Language

ALPG

ALPG Overview

English Name	Alkaline phosphatase	Approved Drugs	1
Drugs in Clinical Trials	3	Target Synonym	Alkaline Phosphatase
Highest Development Stage	Approved

English Name	Alkaline phosphatase
Target Synonym	Alkaline Phosphatase
Approved Drugs	1
Drugs in Clinical Trials	3
Highest Development Stage	Approved

ALPG Product List

Product Category
Protein (3)
Product Status
Launched (3)
Species
Mouse (1)Human (2)
Tag
His Tag (2)His Tag & Avi Tag (1)
Conjugate
Unconjugated (2)Biotin-labeled (1)

Cat. No.	Species	Host	Product Description
HOT ALG-H52H9	Human	HEK293	Human ALPG / ALPPL2 Protein, His Tag, low endotoxin (active enzyme, MALS verified)
ALG-H52E1	Human	HEK293	Biotinylated Human ALPG / ALPPL2 Protein, His,Avitag™ (MALS verified)
ALG-M52H9	Mouse	HEK293	Mouse ALPG / ALPPL2 Protein, His Tag (active enzyme, MALS verified)

Total: 3

ALPG Background

ALPPL2 is specifically highly expressed in naïve pluripotent stem cells. Moreover, in naïve state somatic cell reprogramming, naïve-primed transformation and other systems, the use of the ALPPL2 promoter-driven fluorescent reporter system can specifically indicate the establishment or withdrawal of naïve state pluripotency, thereby identifying ALPPL2 as naïve state pluripotent. specific cell surface markers. Some studies have found that knockout of ALPPL2 can specifically affect the establishment, stability and maintenance of naïve state pluripotency, proving that ALPPL2 protein is a functional naïve state surface molecular marker.

ALPG Synonyms

ALPG,GCAP,ALP-1,ALPPL2,PLAP-like,ALPPL,Alkaline phosphatase, germ cell type

Antibody Project Trading Platform

Project Name	Project Stage	Molecule Type	Molecule Source	Disease Area	Indication
ALPP/ALPPL2 mAb - 01	PCC	Monoclonal	Humanized Mouse	Solid Tumor	Endometrial cancer,Ovarian cancer

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
ALXN-1850	ALXN-1850	Phase 3 Clinical	Alexion Pharmaceuticals Inc	Hypophosphatasia	Details
Amifostine for nasoduodenal delivery (Xerient Pharma)	XER-001	Phase 2 Clinical	Xerient Pharma	Pancreatic Neoplasms	Details
placenta-derived protein (Zoltan)	PALP	Clinical	Zoltan Laboratories	Cachexia; Diabetes Mellitus; Obesity	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	Earliest Brand Name	Earliest Approval Country	Earliest Indication	Earliest Approval Company	Earliest Approval Date	Indication	Clinical Trial
Amifostine	WR-2721C; NSC-296961; YM-08310; S-8744; SAPEP; WR-2721	Approved	Medimmune Llc	Ethyol, 天地达, 安福定	Mainland China	Cytoprotective adjuvant	China Grand Automotive Services Group Co Ltd	1995-12-08	Acute Radiation Syndrome; Bone Marrow Diseases; Breast Neoplasms; Carcinoma; Cytoprotective adjuvant; Fanconi Anemia; Gestational Trophoblastic Disease; Head and Neck Neoplasms; Hodgkin Disease; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Mucositis; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Nasopharyngeal Neoplasms; Neurotoxicity Syndromes; Neutropenia; Ovarian Neoplasms; Peripheral Nervous System Diseases; Prostatic Neoplasms; Salivary Gland Diseases; Sarcoma; Solid tumours; Trigeminal Neuralgia	Details